The Scientific Advisory Board Will Develop the Company Clinical Trial Strategy, Ensure Alignment with Current…
Pacertool is solving a 20 year old problem to understand how to effectively measure the underlying mechanisms for the development of dyssynchronus heart failure. The measurement can be used as a biomarker with the ability to improve the outcome in heart failure patients. To do so, Pacertool aims to be first to market in the US and Europe with a proprietary medical device to address this unmet medical need.
Currently, 30-40% of the heart failure patients needing resynchronization therapy have limited effect of a biventricular pacemaker (CRT) implantation and around 10% of the patients are fearing worse after the implant. This affects around 40,000 patients per year and constitutes an estimated annual burden of more than USD 1B to the healthcare systems in the US and Europe. Promoting value-based healthcare, Pacertool has the potential to reduce these costs and at the same time increase the market and effectiveness of the implanted pacemakers.
Pacertool will over the next years develop the complete Pacertool system and will enter into clinical and regulatory processes to validate the technology. The company targets the US market with a staged regulatory strategy utilizing already approved devices before establishing clinical data for unique indications for use.
The company was founded by Dr. Hans Henrik Odland in 2019 and has completed the first proof-of-principle clinical trial in 45 heart failure patients. Pacertool has established a dedicated team of medical device professionals in Oslo, Norway. The team has a deep understanding of R&D processes for SW, hardware, and advanced intracardiac electrophysiology catheters.
Pacertool is here to deliver the right treatment to the right heart failure patients at the right time.
We will address the “Why?” question by focusing on three main objectives:
- We will be first to market with technologies that improve the outcomes for heart failure patients with dyssynchronous heart failure and reduced ejection fraction (HFrEF); and
- We will improve the survival chances the quality of life for HFrEF patients by optimizing the pacing approaches selected for these patients; and finally
- We will improve the workflow for the implanting physician by offering an operator agnostic, easy-to-use diagnostic tool that optimizes the pacemaker implantation.
At the core of the company lies our values which are:
Iterate from Plan A to a Plan that Works
Pacertool supports a learning environment where you are allowed to take risks, learn from your mistakes and succeed. We do accept that we can start with an initial plan and learn on our way thereby iterating to a plan that works. This is part of a lean development philosophy described well in the book “Running Lean” by Ash Maurya.
We are Here Because of an Opportunity
Celebrating success means looking back at achievements and this could lead to losing sight of the vision and goals. We therefor celebrate opportunities, looking forward keeping the vision in sight! What’s the next task? We celebrate opportunities that can bring us closer to the goal! A new task is an opportunity that brings us towards our goals and visions.
Our Company is Built on Trust
At Pacertool we believe that great achievements are founded on ethical behavior, ability to compromise, transparency, and long-term integrity. These values are not only promoted within the company’s culture but are also reflected in our cooperation with external stakeholders.
“Vi Spiller Hverandre Gode!”
The best translation of this Norwegian expression is “I pass the puck so that you can score”. In other words: Pacertool promotes a collaborative work environment where the exchange of information and ideas are critical to the company.
A Strong Sense of Community
Pacertool is creating a community where experts are encouraged to freely exchange ideas, continuously learn from one another and cooperate across disciplines, where everyone is treated fairly and with respect.
“Push, Push, Push!” A Strong Sense of Belonging to a Team that Supports You Moving Forward
Be the one in the team that enables a push forward! Be the one in the team to push forward towards the goal! Help team members move forward, explain, guide, inform, and motivate! Strengthen the engine! Point to any mistake, fault, or pushback that could prevent a push! Get out of your comfort zone!
Pacertool is dedicated to providing uncompromised quality products and effective solutions to healthcare professionals and patients by always complying with applicable national and international regulatory requirements.
We strive for continuous improvement and believe that listening to customer needs and meeting market needs are key to optimal product quality.
Pacertool follows an ISO13485:2016 compliant quality management system, certified by BSI, our Notified Body.
Pacertool has recently closed a seed financing round supported by a prominent Norwegian investor consortium: TD Veen/p53, Sarsia Seed and the Rasmussen Group. The company has also received public funding through the Norwegian Research Council, Innovation Norway and the European Union.
Our investors have a long-term perspective of building a successful medical device company and has a track record of supporting other successful Norwegian biotech and medical device companies such as Nykode (Vaccibody) and BerGenBio. In the words of TD Veen/p53: “We seek to contribute to the development and commercialization of groundbreaking ideas that will increase accessibility to cutting-edge treatments and innovative solutions with positive effect on quality of life and well-being”.
Pacertool has also secured non-dilutive funding from the Research Council of Norway, Innovation Norway and through the Eureka Eurostars program.
We are welcoming new investors who share the Pacertool vision of precision treatment of heart failure patients.
For further information please contact our CEO, Jon H. Hoem, at firstname.lastname@example.org or call at +47 97 30 30 09.
We are pleased to announce that Pacertool has been granted 7.5M NOK by the Research…